BioNTech publishes proof-of-concept data for BNT211 CAR-T cell therapy
Category: #health  | By Mateen Dalal  | Date: 2020-01-04 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

BioNTech publishes proof-of-concept data for BNT211 CAR-T cell therapy

The report will contain data of CAR-T product candidate called BNT211, an autologous CAR-T cell therapy

BioNTech SE, a biotechnology firm based in Germany, recently announced a publication in Science regarding a therapeutic CAR-T approach for solid tumors that uses CAR-T cell amplifying RNA Vaccine, also called CARVac introduced by the company. The report offers preclinical proof-of-concept data for the company’s first CAR-T product candidate called BNT211 which is an autologous CAR-T cell therapy.

It essentially targets oncofetal antigen Claudin 6 (CLDN6) as well as outlines CARVac as an RNA vaccine approach that is widely applicable for the improvement of the efficacy of the CAR-T cell therapies.

Reportedly, CAR-T cell has exhibited considerable clinical efficacy in blood cancers but still tends to face challenges in regards with solid tumors that includes a limited number of identified cancer-specific solid tumors, insufficient persistence of CAR-T cells and inefficient CAR-T cell infiltration into solid tumors.

BioNTech has been aiming to overpower such hurdles by targeting the tumor-specific antigen expressed in several solid tumors, CLDN6, which when combined with an RNA vaccine will promote persistence, efficacy, and amplification of CAR-T cells in vivo.

CAR-T cell therapy combined with CARVac will be underlining the value of cross-platform synergies that would address major challenges for the development of cancer treatment.

Sources confirm that BioNTech has planned to commence Phase 1/2 clinical trial, its first-in-human trial for BNT211, later in the year in solid tumors such as testicular, lung cancer, ovarian and uterine. The manufacturing shall be conducted in-house at the state-of-the-art cell therapy facility BioNTech, which is GMP certified, to support the clinical trials of BNT211. The GMP plant is a certified cell therapy and manufacturing facility located in Idar-Oberstein, Germany, that has been operating since 1999.

BioNTech had initiated a capacity expansion at the facility in the year 2018 and it expects it to be completed by 2020.

 

Source Credit- https://investors.biontech.de/news-releases/news-release-details/biontech-announces-publication-preclinical-data-first-kind-car-t

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Russia-Ukraine war puts UK fish & chips industry in severe jeopardy

Russia-Ukraine war puts UK fish & chips industry in severe jeopardy

By Mateen Dalal

The on-going conflict between Russia and Ukraine has adversely affected the fish and chips industry in the United Kingdom, driving the closure of centuries-old shops, sharp price hikes, and change in menus. The National Federation of Fish Friers (...

U.S Govt. pledges $3.16 bn funding to boost EV battery manufacturing

U.S Govt. pledges $3.16 bn funding to boost EV battery manufacturing

By Mateen Dalal

The U.S. Department of Energy (DOE) has reportedly announced funds of $3.16 billion from President Joe Biden’s ‘Bipartisan Infrastructure Law’ for bolstering the domestic battery manufacturing and supply chain and creating more jobs...

Ammann rolls out new ADS technology to analyze jobsite compaction data

Ammann rolls out new ADS technology to analyze jobsite compaction data

By Mateen Dalal

Swiss mechanical engineering company Ammann has reportedly introduced a new ADS (Ammann Documentation System) technology. This new technology is geared towards capturing and further analyzing jobsite compaction data, which can lead to improved qualit...